Editas Medicine Inc

Editas Medicine Inc a clinical stage genome editing company focuses on developing transformative genomic medicines to treat a range of serious diseases It develops a proprietary gene editing platform based on CRISPR technology The company develops EDIT101 which is in Phase 12 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness It also develops EDIT102 for the treatment of Usher Syndrome 2A which is a form of retinitis pigmentosa that also includes hearing loss autosomal dominant retinitis pigmentosa a progressive form of retinal degeneration and EDIT301 to treat sickle cell disease and transfusiondependent betathalassemia In addition the company is developing geneedited Natural Killer cell medicines to treat solid tumor cancers alphabeta T cells for multiple cancers and gamma delta T cell therapies to treat cancer as well as has an early discovery program to develop a therapy to treat a neurological disease It has a research collaboration with Juno Therapeutics Inc to develop engineered T cells for cancer strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover develop and commercialize new gene editing medicines for a range of ocular disorders and research collaboration with Asklepios BioPharmaceutical Inc to develop a therapy to treat a neurological disease as well as research collaboration with AskBio The company was formerly known as Gengine Inc and changed its name to Editas Medicine Inc in November 2013 Editas Medicine Inc was incorporated in 2013 and is based in Cambridge Massachusetts